Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Smuggling of anti...

    Smuggling of anti cancer drug in India worth Rs 1.23 crore, Chinese arrested at airport

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-06T13:45:47+05:30  |  Updated On 6 March 2019 1:45 PM IST
    Smuggling of anti cancer drug in India worth Rs 1.23 crore, Chinese arrested at airport

    Schedule H drugs are prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.


    NEW DELHI: In a major crackdown, the customs officials have arrested a Chinese man at the Delhi airport for allegedly trying to smuggle out anti-cancer medicine worth Rs 1.23 crore, according to an official statement issued on Tuesday. The accused was intercepted when he was proceeding to depart to Kunming in China on Sunday.


    Also Read: Delhi Police Busts Painkiller Racket in the capital- 46,000 capsules of Tramadol Seized


    "A detailed examination of hand baggage and check-in bags of the passenger resulted in the recovery of schedule H medicines valued at Rs 1.23 crore," the customs department said in the statement.



    Schedule H is a part of the Drugs and Cosmetics Act, 1940. The Drugs and Cosmetics Act, 1940 has 25 Schedules, Schedule H is one among them.
    Schedule H is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.


    The drugs were kept in the four check-in bags of the passenger, it said. Official sources said the medicine was meant for cancer treatment.


    The Chinese man has been arrested and the drugs were seized.


    Also Read: 18 held for smuggling banned medicinal plants in Bandipora




    In 2017, the ministry of Health and Family Welfare had amended the Drugs and Cosmetics Rules, 1945, in Schedule H by adding the following entries after the serial number 537 namely,- 538. Alclometasone, 539. Beclomethasone, 540. Betamethasone, 541. Desonide, 542. Desoximetasone, 543. Dexamethasone, 544. Diflorasone diacetate, 545. Fluocinonide, 546. Fluocinolone acetonide, 547. Halobetasol propionate, 548. Halometasone, 549. Methylprednisone, 550. Prednicarbate, 551. Triamcinolone acetonide”


    Also Read: MORE DRUGS added to the Schedule H list


    Medical Dialogues had recently reported that the government has brought 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 per cent, which would reduce their retail prices by up to 85 per cent. These would cover 72 formulations and 355 brands as per data available with NPPA.



    Also Read: NPPA caps trade margins to 30 percent for 42 cancer drugs


    AIIMSanti-cancer drugcancercancer drugchinese manDelhi airportDNBdrug smugglingGeorge Washington UniversityMCIPGs in emergency medicineSchedule Hschedule H drugschedule H drugssmugglingsociety for emergency medicine in india
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok